The pump is 21 French across and spins at up to 33,000 revolutions per minute. Its motor stays outside the body and turns a flexible shaft that drives a microaxial pump inside the patient, moving up to six litres of blood a minute.
FloAID Medtech builds it at IIT Madras Research Park in Chennai. The company was registered in 2024 and is part of ARTPARK’s startup portfolio, which describes it in a line: artificial heart pumps that integrate AI and ML.
A surgeon’s need, an engineer’s design.
“Patients whose hearts are failing need life support that Indian hospitals can afford. We are building it here, and proving every step before it reaches a patient.”
Shiv Gupta is a biomedical scientist who trained at IIT Madras and NTU Singapore, with experience in biomedical design, fabrication, system integration and programme management. He leads product development as CEO.
The clinical need was validated with Dr. K Balakrishnan, Director of Heart and Lung Transplant at MGM Hospital. The company says he performed the first LVAD and HVAD pump transplants in India. His role in the team covers the expert user’s view and the animal and clinical trials. Purrshottam Bhaggeria, Joint Managing Director of Filatex India, supports business management and industrial collaborations. FloAID’s website presents the three as its founding trio.
Two pumps on one console.
FloAID is building for cardiologists and surgeons in three hard situations: high-risk angioplasty, cardiogenic shock and open-heart surgery. Its catheter pump has separate channels for the left and right sides of the heart on a single controller, which the company calls India’s first dual cath pump.
A percutaneous ventricular assist device: an intravascular microaxial pump with an external motor and flexible shaft drive, up to 6 litres a minute. Pre-clinical, and not for clinical use.
One console that can run left- and right-heart support.
A heart-lung machine for cardiopulmonary bypass, up to 11 litres a minute, with master and slave pump control. The company plans to commercialise it in 2026.
The company reports more than 12 patents filed and one granted.
From the bench to animal trials.
A heart pump has to pass through test benches, animal studies and regulators before it reaches a patient. FloAID’s roadmap shows where it stands on that path. These are the company’s own milestones; no independent coverage has been published yet.
- FloAID, team. floaid.com
- FloAID, products and roadmap. floaid.com
- FloAID, contact (IIT Madras Research Park). floaid.com
- ARTPARK, startup portfolio. artpark.in
